결핵 진료지침
11. Jeon K, Choi WI, An JS, et al. Paradoxical response in HIV-negative patients with pleural tuberculosis: a retrospective multicentre study. Int J Tuberc Lung Dis. 2012;16:846-851.
12. Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2019;19:1129-1137.
13. Choi H, Han K, Jung JH, Park SH, Kim SH, Kang HK, et al. Long-Term Mortality of Tuberculosis Survivors in Korea: A Population-based Longitudinal Study. Clin Infect Dis 2023;76:e973-e981.
14. Akkerman OW, Duarte R, Tiberi S, Schaaf HS, Lange C, Alffenaar JWC, et al. Clinical standards for drug-susceptible pulmonary TB. Int J Tuberc Lung Dis 2022;26:592-604.
15. Johnston JC, Cooper R, Menzies D. Chapter 5: Treatment of tuberculosis disease. In: Menzies D, ed. Canadian Tuberculosis Standards. 8th ed. Ottawa: Canadian Thoracic Society; 2022.
16. Vega V, Rodriguez S, Stuyft PVD, Seas C, Otero L. Recurrent TB: a systematic review and meta-analysis of the incidence rates and the proportions of relapses and reinfections. Thorax 2021;76:494-502.
17. Youn HM, Shin MK, Jeong D, Kim HJ, Choi H, Kang YA. Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study. PLoS one 2022;17:e0268290.
18. Nunn AJ, Phillips PP, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 2010;14:241-2.
19. Allwood BW, van der Zalm MM, Amaral AFS, Byrne A, Datta S, Egere U, et al. Post-tuberculosis lung health: perspectives from the First International Symposium. Int J Tuberc Lung Dis 2020;24:820-8.
20. Allwood BW, Byrne A, Meghji J, Rachow A, Van Der Zalm MM, et al. Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge. Respiration 2021;100:751-63.

II. 결핵의 치료 <PAGE>57